Promising new epilepsy drug delivers 80% reduction in seizures
A new epilepsy drug candidate, RAP-219, is showing remarkable promise for people whose seizures have not responded to existing treatments. In a Phase 2a trial led by Rapport Therapeutics with support from NYU Langone Health, nearly one-quarter of participants became seizure-free, while most saw their seizures cut by more than half. Using advanced neurostimulation devices to track brain activity, researchers confirmed the drug’s targeted effects and manageable side-effect profile. If larger studies confirm these results, RAP-219 could offer new hope for patients living with drug-resistant epilepsy.









